Abstract
Drug resistance remains one of the most formidable challenges in cancer therapy. Despite advances in targeted treatments and personalized medicine, many cancers eventually develop resistance to chemotherapeutic agents. This article explores the underlying mechanisms of drug resistance in cancer, including genetic mutations, epigenetic alterations, drug efflux, tumor microenvironment influences, and cancer stem cells. Understanding these mechanisms is essential for the development of novel strategies to overcome resistance and improve therapeutic outcomes.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.